215 related articles for article (PubMed ID: 12746909)
1. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis.
Hu PQ; Fertig N; Medsger TA; Wright TM
Arthritis Rheum; 2003 May; 48(5):1363-73. PubMed ID: 12746909
[TBL] [Abstract][Full Text] [Related]
2. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
Perera A; Fertig N; Lucas M; Rodriguez-Reyna TS; Hu P; Steen VD; Medsger TA
Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
[TBL] [Abstract][Full Text] [Related]
3. Anti-DNA topoisomerase II alpha autoantibodies in Japanese patients with systemic sclerosis.
Hayakawa I; Hasegawa M; Takehara K; Sato S
Arch Dermatol Res; 2005 Oct; 297(4):180-3. PubMed ID: 16180014
[TBL] [Abstract][Full Text] [Related]
4. Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress.
Iwata Y; Ogawa F; Komura K; Muroi E; Hara T; Shimizu K; Hasegawa M; Fujimoto M; Tomita Y; Sato S
Rheumatology (Oxford); 2007 May; 46(5):790-5. PubMed ID: 17309887
[TBL] [Abstract][Full Text] [Related]
5. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis.
Hénault J; Tremblay M; Clément I; Raymond Y; Senécal JL
Arthritis Rheum; 2004 Oct; 50(10):3265-74. PubMed ID: 15476238
[TBL] [Abstract][Full Text] [Related]
6. Diversity and plasticity of the anti-DNA topoisomerase I autoantibody response in scleroderma.
Henry PA; Atamas SP; Yurovsky VV; Luzina I; Wigley FM; White B
Arthritis Rheum; 2000 Dec; 43(12):2733-42. PubMed ID: 11145031
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis.
Kuwana M; Kaburaki J; Mimori T; Kawakami Y; Tojo T
Arthritis Rheum; 2000 May; 43(5):1074-84. PubMed ID: 10817562
[TBL] [Abstract][Full Text] [Related]
8. Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis.
Hara T; Ogawa F; Muroi E; Komura K; Takenaka M; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2008 Mar; 35(3):451-7. PubMed ID: 18203319
[TBL] [Abstract][Full Text] [Related]
9. Elevation of IgG levels is a serological indicator for pulmonary fibrosis in systemic sclerosis with anti-topoisomerase I antibodies and those with anticentromere antibody.
Komura K; Yanaba K; Ogawa F; Shimizu K; Takehara K; Sato S
Clin Exp Dermatol; 2008 May; 33(3):329-32. PubMed ID: 18312458
[TBL] [Abstract][Full Text] [Related]
10. IgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patients.
García de la Peña-Lefebvre P; Chanseaud Y; Tamby MC; Reinbolt J; Batteux F; Allanore Y; Kahan A; Meyer O; Benveniste O; Boyer O; Guillevin L; Boissier MC; Mouthon L
Clin Immunol; 2004 Jun; 111(3):241-51. PubMed ID: 15183145
[TBL] [Abstract][Full Text] [Related]
11. Rheumatoid factor isotypes and anti-agalactosyl IgG antibodies in systemic sclerosis.
Mimura Y; Ihn H; Jinnin M; Asano Y; Yamane K; Yazawa N; Tamaki K
Br J Dermatol; 2004 Oct; 151(4):803-8. PubMed ID: 15491420
[TBL] [Abstract][Full Text] [Related]
12. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K
Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
[TBL] [Abstract][Full Text] [Related]
13. Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations.
Kodera M; Hayakawa I; Komura K; Yanaba K; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2005 Apr; 32(4):629-36. PubMed ID: 15801017
[TBL] [Abstract][Full Text] [Related]
14. T and B cell collaboration is essential for the autoantibody response to DNA topoisomerase I in systemic sclerosis.
Kuwana M; Medsger TA; Wright TM
J Immunol; 1995 Sep; 155(5):2703-14. PubMed ID: 7650398
[TBL] [Abstract][Full Text] [Related]
15. Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma.
Hayakawa I; Hasegawa M; Takehara K; Sato S
Arthritis Rheum; 2004 Jan; 50(1):227-32. PubMed ID: 14730620
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies against calpastatin in sera from patients with systemic sclerosis.
Sato S; Hasegawa M; Nagaoka T; Takamatsu Y; Yazawa N; Ihn H; Kikuchi K; Takehara K
J Rheumatol; 1998 Nov; 25(11):2135-9. PubMed ID: 9818655
[TBL] [Abstract][Full Text] [Related]
17. Naturally occurring and disease-associated auto-antibodies against topoisomerase I: a fine epitope mapping study in systemic sclerosis and systemic lupus erythematosus.
Simon D; Czömpöly T; Berki T; Minier T; Peti A; Tóth E; Czirják L; Németh P
Int Immunol; 2009 Apr; 21(4):415-22. PubMed ID: 19211583
[TBL] [Abstract][Full Text] [Related]
18. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis.
Kim D; Peck A; Santer D; Patole P; Schwartz SM; Molitor JA; Arnett FC; Elkon KB
Arthritis Rheum; 2008 Jul; 58(7):2163-73. PubMed ID: 18576347
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of serum hyaluronan levels in systemic sclerosis: association with disease severity.
Yoshizaki A; Iwata Y; Komura K; Hara T; Ogawa F; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2008 Sep; 35(9):1825-9. PubMed ID: 18688912
[TBL] [Abstract][Full Text] [Related]
20. Immunization with DNA topoisomerase I induces autoimmune responses but not scleroderma-like pathologies in mice.
Hu PQ; Hurwitz AA; Oppenheim JJ
J Rheumatol; 2007 Nov; 34(11):2243-52. PubMed ID: 17937466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
